Health

ACIP recommends high-dose influenza vaccine for patients over 65 years of age

This flu season comes at an important time, as COVID-19 precautions have raised concerns about rebounding after a low number in the last few years.

As the United States prepares for the next influenza season, the Centers for Disease Control and Prevention’s Immunization Implementation Advisory Committee (ACIP) prioritizes the use of differentiated influenza vaccines for adults age 65 and older. Recommended. Prior to this recommendation, there was no preferred influenza vaccine for the elderly. Also, since 2010, the latest ACIP recommendations for influenza vaccines for this population have not been made.

This recommendation is made at a lucky time as the United States prepares for the next flu season, as people over the age of 65 are particularly vulnerable to the flu and can cause life-threatening complications. Due to COVID-19 precautions being taken, influenza cases are rare and these precautions are minimized, so influenza cases are expected to recover and older people are at increased risk again. increase. With this in mind, the ACIP recommendations are that not all influenza vaccines are made the same, and this sensitive population needs better protection than those offered by standard dose vaccines. I support that.

Seasonal flu is a serious illness that affects imbalances in people over the age of 65 and can lead to pneumonia, serious heart disease, hospitalization, and death. Other people who are particularly prone to complications are people of color and those with comorbidities such as diabetes, asthma, chronic obstructive pulmonary disease, and heart disease.

“We recommend that ACIP recommends a flu vaccine tailored for adults over the age of 65, which is the first to develop clearer guidance on prevention of influenza in this high-risk population. I believe it is a step, “said Christopharizzo Medical Doctor, Senior Medical Director, USA.Sanofi, the manufacturer of recommended vaccines, has its own press release.. “We hope that this recommendation means that more adults over the age of 65 will be immunized with the influenza vaccine that best suits their needs. The clinical data and actual evidence available are influenza infections. The CDC clearly supports the differentiated influenza vaccine as it is more effective than standard dose vaccines in the prevention of influenza and helps reduce the burden of illness and minimize health disparities in the U.S. population. I’m looking forward to the final decision. “

The recommended influenza vaccine, Fluzone® High-Dose Quadrivalent, is touted as the first and only influenza vaccine with excellent influenza prevention and 10 years of evidence. [from 2009-2019] For prevention of influenza-related hospitalization for adults over 65 years old.

advance press release Sanofi urged ACIP to include a description of the Sanofi influenza high-dose vaccine for vaccines over the age of 65. Over ages showing superior efficacy in randomized controlled trials compared to standard dose influenza vaccines for the prevention of influenza disease confirmed in the laboratory, influenza and related complications The only influenza vaccine with 10 years of data showing protection from. In an actual analysis of about 34 million people, those who received Fluzone High-Dose had an 18% reduction in cardiorespiratory hospitalization and a 27% or more reduction in pneumonia hospitalization. Both are reduced compared to standard dose vaccines. sponsored. “

ExBulletin

ACIP recommends high-dose influenza vaccine for patients over 65 years of age